Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Autosomal Dominant Polycystic Kidney Disease (ADPKD): early-phase trial registry
2 of 6 indexed Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Autosomal Dominant Polycystic Kidney Disease (ADPKD): 6 US clinical trials tracked, 2 recruiting.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Vertex Pharmaceuticals Incorporated, running 4 of these trials.
Enrollment posture brief
Registry condition autosomal-dominant-polycystic-kidney-disease-adpkd
OPEN 2 | RECR 33% | LATE 0 | EARLY 3 | RANK #2866 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Autosomal Dominant Polycystic Kidney Disease (ADPKD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is recruiting below its size-band peers.
2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Autosomal Dominant Polycystic Kidney Disease (ADPKD) research.
Vertex Pharmaceuticals Incorporated accounts for 4 of 6 trials (66.7%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials plan to enrol fewer than 100 people.
Median target enrolment is 74 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Autosomal Dominant Polycystic Kidney Disease (ADPKD) splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Vertex Pharmaceuticals Incorporated
NCT07161037
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
Richard Fatica
NCT07454174
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
Vertex Pharmaceuticals Incorporated
NCT06747572
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
Vertex Pharmaceuticals Incorporated
NCT07074327
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
Vertex Pharmaceuticals Incorporated
NCT07022119
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
Otsuka Pharmaceutical Development & Commercialization
NCT01430494
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Autosomal Dominant Polycystic Kidney Disease (ADPKD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Autosomal Dominant Polycystic Kidney Disease (ADPKD) page
6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vertex Pharmaceuticals Incorporated sponsors the most Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials on record, review their full trial history before evaluating a specific study. See Vertex Pharmaceuticals Incorporated's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Autosomal Dominant Polycystic Kidney Disease (ADPKD) condition card totals 6 registered trials; most-linked intervention VX-407; top US site state Kansas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.